Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Roy Barry Tishler, Ph.D., M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Roy Tishler and Jonathan Schoenfeld.
Roy Tishler
Connection Strength
4.769
Jonathan Schoenfeld
  1. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):308-14.
    View in: PubMed
    Score: 0.452
  2. Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. Head Neck. 2022 Mar 31.
    View in: PubMed
    Score: 0.249
  3. Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. Head Neck. 2022 03; 44(3):722-734.
    View in: PubMed
    Score: 0.244
  4. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570.
    View in: PubMed
    Score: 0.224
  5. Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head Neck. 2020 12; 42(12):3670-3677.
    View in: PubMed
    Score: 0.223
  6. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):134-144.
    View in: PubMed
    Score: 0.222
  7. Outcomes following radiation for cutaneous squamous cell carcinoma of the head and neck: Associations between immune suppression and recurrence. Head Neck. 2019 07; 41(7):2111-2115.
    View in: PubMed
    Score: 0.200
  8. IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019 04; 41(4):959-966.
    View in: PubMed
    Score: 0.199
  9. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):137-145.
    View in: PubMed
    Score: 0.192
  10. Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncol. 2017 10; 73:160-165.
    View in: PubMed
    Score: 0.181
  11. Prospective analysis of radiation oncology image and plan-driven peer review for head and neck cancer. Head Neck. 2017 08; 39(8):1603-1608.
    View in: PubMed
    Score: 0.178
  12. Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19(2):129-136.
    View in: PubMed
    Score: 0.173
  13. Merkel Cell Carcinoma: A Population Analysis on Survival. J Natl Compr Canc Netw. 2016 10; 14(10):1247-1257.
    View in: PubMed
    Score: 0.170
  14. Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncol. 2016 10; 61:19-26.
    View in: PubMed
    Score: 0.168
  15. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60.
    View in: PubMed
    Score: 0.167
  16. Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer. 2016; 4:32.
    View in: PubMed
    Score: 0.167
  17. Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple. BJR Case Rep. 2016; 2(1):20150271.
    View in: PubMed
    Score: 0.162
  18. Radiation Oncology--New Approaches in Squamous Cell Cancer of the Head and Neck. Hematol Oncol Clin North Am. 2015 Dec; 29(6):1093-106.
    View in: PubMed
    Score: 0.160
  19. Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual center retrospective study. J Am Acad Dermatol. 2022 Mar 29.
    View in: PubMed
    Score: 0.062
  20. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478.
    View in: PubMed
    Score: 0.060
  21. Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists. Adv Radiat Oncol. 2021 May-Jun; 6(3):100608.
    View in: PubMed
    Score: 0.057
  22. Association between treatment center experience and survival after diagnosis of stage I to III Merkel cell carcinoma treated with surgery with or without postoperative radiation therapy. J Am Acad Dermatol. 2021 Mar; 84(3):875-877.
    View in: PubMed
    Score: 0.056
  23. Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 2021 01; 112:105087.
    View in: PubMed
    Score: 0.056
  24. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist. 2020 07; 25(7):598-608.
    View in: PubMed
    Score: 0.054
  25. Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 2020 07; 106:104690.
    View in: PubMed
    Score: 0.054
  26. Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2020 06; 105:104676.
    View in: PubMed
    Score: 0.054
  27. Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status. Cancer. 2020 04 01; 126(7):1424-1433.
    View in: PubMed
    Score: 0.053
  28. Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019 10; 28(10):1660-1667.
    View in: PubMed
    Score: 0.052
  29. A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):132-139.
    View in: PubMed
    Score: 0.051
  30. Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106.
    View in: PubMed
    Score: 0.050
  31. Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):34-43.
    View in: PubMed
    Score: 0.048
  32. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 11; 22(11):1413.
    View in: PubMed
    Score: 0.046
  33. Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Front Oncol. 2017; 7:191.
    View in: PubMed
    Score: 0.045
  34. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 03; 22(3):343-350.
    View in: PubMed
    Score: 0.044
  35. Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. Head Neck. 2016 10; 38(10):1530-8.
    View in: PubMed
    Score: 0.041
  36. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2016 06 15; 22(12):2939-49.
    View in: PubMed
    Score: 0.040
  37. Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era. Cancer. 2015 Aug 01; 121(15):2594-602.
    View in: PubMed
    Score: 0.038
  38. Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Oncol Pract. 2015 Mar; 11(2):151-4.
    View in: PubMed
    Score: 0.038
  39. Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Clin Oncol. 2014 Oct 20; 32(30_suppl):100.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.